Find latest Breast videos · 400+ videos
Lilly Medical Affairs
K

SERDS: Relevance and Role in Current & Future Treatments for HR+, HER2- MBC

By Lilly Medical Affairs FEATURING Komal Jhaveri
By Lilly Medical Affairs FEATURING Komal Jhaveri
751 views
July 24, 2024

In this video, Dr. Komal Jhaveri shares her expertise on SERDs for the treatment of HR+, HER2- MBC, including the evolving role of novel oral SERDs.

To access additional videos and download free resources, click here.

VV-OTHR-US-DEL-3129 © 2024 Lilly USA, LLC. All Rights Reserved.

Comments are disabled for this content.

Featured Video

05:15
Lilly Medical Affairs

Unmet Needs for Patients With HR+, HER2- Early Breast Cancer at a Hi…

Feat. H. Rugo

Featured Video

11:11
Lilly Medical Affairs

Supporting Patients With Breast Cancer in the Clinic: Setting the Pa…

Feat. S. Dawood

Related Videos

02:58
Lilly Medical Affairs

A Heterogenous Disease with Varied Clinical Outcomes: HR+/HER2- MBC

Feat. J. O’Shaughnessy
06:14
Lilly Medical Affairs

CDK4/6 Inhibitors as First-Line Treatment for HR+, HER2- MBC

Feat. J. O’Shaughnessy
05:59
Lilly Medical Affairs

Progression on First-Line Therapy in HR+, HER2- MBC: Treatments and …

Feat. J. O’Shaughnessy
03:57
Lilly Medical Affairs

Resistance Mechanisms to ET, Including ESR1 Mutations in HR+, HER2- …

Feat. K. Jhaveri
03:15
Lilly Medical Affairs

Unmet Needs and Resistance Mechanisms in Patients With HR+, HER2- MB…

Feat. W. Mchayleh
25:08

ASCO® 2024 Breast Cancer Highlights - Monday Morning Practice

2024 ASCO® Annual Meeting Insights Hub

S. Tolaney, H. Rugo

4.4K views
06:40
Lilly Medical Affairs

Communicating the Risk of Recurrence for Patients With HR+, HER2- Ea…

Feat. J. O’Shaughnessy
06:39

FDA Approval Clinical Implications: Inavolisib With Palbociclib and …

Memorial Sloan Kettering Cancer Center

K. Jhaveri

754 views
12:14

ASCO® 2024 Breast Cancer Highlights: Top 5 Abstracts - DESTINY-Breas…

2024 ASCO® Annual Meeting Insights Hub

P. Tarantino

2.2K views
06:14
Lilly Medical Affairs

CDK4/6 Inhibitors as First-Line Treatment for HR+, HER2- MBC

Feat. J. O’Shaughnessy
05:59
Lilly Medical Affairs

Progression on First-Line Therapy in HR+, HER2- MBC: Treatments and …

Feat. J. O’Shaughnessy
10:53

Integrating Oral Therapy for Patients With HR+/HER2- Early Stage BC

Kirollos Hanna

2.3K views
06:51

SABCS 2024 Noteworthy Abstracts in Metastatic Breast Cancer

Sara Tolaney

H. Rugo

662 views
17:12

Strategies for Managing Toxicities of Oral Oncolytics in Breast Canc…

UNC Lineberger Comprehensive Cancer Center

A. Faso, B. Patel, K. Chen

1.6K views
08:49

ESMO 2024 Insights: Treatment Rechallenge After Grade 1 Trastuzumab-…

2024 ESMO Annual Meeting Insights Hub

K. Natsuhara

856 views
15:57

SABCS 2024 Noteworthy Abstracts in Early Breast Cancer

Sara Tolaney

H. Rugo

625 views
14:52

ESMO 2024 Summary: Top 5 Breast Cancer Abstracts - NATALEE, DESTINY-…

2024 ESMO Annual Meeting Insights Hub

P. Tarantino

850 views
03:15
Lilly Medical Affairs

Unmet Needs and Resistance Mechanisms in Patients With HR+, HER2- MB…

Feat. W. Mchayleh
02:58
Lilly Medical Affairs

A Heterogenous Disease with Varied Clinical Outcomes: HR+/HER2- MBC

Feat. J. O’Shaughnessy
09:55

ASCO® 2024 Insights: "The ABCs of ADCs - What Does the Future Hold?"

2024 ASCO® Annual Meeting Insights Hub

E. Hamilton

1.5K views
AUTOPLAY